Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

948 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
"Timing" of arrival and in-hospital mortality in a cohort of patients under anticoagulant therapy presenting to the emergency departments with cerebral hemorrhage: A multicenter chronobiological study in Italy.
Fabbian F, Manfredini R, De Giorgi A, Gallerani M, Cavazza M, Grifoni S, Fabbri A, Cervellin G, Ferrari AM, Imberti D; PROMPT Registry Investigators. Fabbian F, et al. Among authors: fabbri a. Chronobiol Int. 2016;33(3):245-56. doi: 10.3109/07420528.2015.1133636. Epub 2016 Feb 6. Chronobiol Int. 2016. PMID: 26852790
Consensus paper on the management of acute isolated vertigo in the emergency department.
Vanni S, Vannucchi P, Pecci R, Pepe G, Paciaroni M, Pavellini A, Ronchetti M, Pelagatti L, Bartolucci M, Konze A, Castellucci A, Manfrin M, Fabbri A, de Iaco F, Casani AP; Società Italiana di Medicina d’Emergenza Urgenza [SIMEU], Società Italiana di Vestibologia [VIS]. Vanni S, et al. Among authors: fabbri a. Intern Emerg Med. 2024 Aug;19(5):1181-1202. doi: 10.1007/s11739-024-03664-x. Epub 2024 Jul 13. Intern Emerg Med. 2024. PMID: 39001977 Free PMC article.
[ANMCO/SIMEU Consensus document on the use of reversal agents of antithrombotic therapies in patients with active bleeding or at high-risk of major bleeding events].
De Luca L, Pugliese FR, Susi B, Navazio A, Corda M, Fabbri A, Scicchitano P, Voza A, Vanni S, Bilato C, Geraci G, Gabrielli D, Grimaldi M, Colivicchi F, De Iaco F, Oliva F. De Luca L, et al. Among authors: fabbri a. G Ital Cardiol (Rome). 2024 Jan;25(1):60-69. doi: 10.1714/4165.41594. G Ital Cardiol (Rome). 2024. PMID: 38141000 Italian.
ANMCO/SIMEU consensus document on the use of reversal agents for antithrombotic therapies in patients with ongoing bleeding or at high risk of haemorrhagic events.
De Luca L, Pugliese FR, Susi B, Navazio A, Corda M, Fabbri A, Scicchitano P, Voza A, Vanni S, Bilato C, Geraci G, Gabrielli D, Grimaldi M, Colivicchi F, De Iaco F, Oliva F. De Luca L, et al. Among authors: fabbri a. Eur Heart J Suppl. 2024 May 16;26(Suppl 2):ii211-ii220. doi: 10.1093/eurheartjsupp/suae033. eCollection 2024 Apr. Eur Heart J Suppl. 2024. PMID: 38784674 Free PMC article.
Longitudinal Assessment of FT3 to FT4 Conversion Ratio in Predicting the Efficacy of First-Line Pembrolizumab-Based Therapy in Advanced Non-Small Cell Lung Cancer: A Propensity-Score Matching Analysis of Data from the National Drug Monitoring Agency.
Nelli F, Ruggeri EM, Schirripa M, Virtuoso A, Giannarelli D, Raso A, Remotti D, Fabbri A. Nelli F, et al. Among authors: fabbri a. Curr Oncol. 2024 Dec 1;31(12):7647-7662. doi: 10.3390/curroncol31120564. Curr Oncol. 2024. PMID: 39727687 Free PMC article.
Immunodeficiency-related high-grade B-cell lymphoma with 11q aberration: Further evidence for a lymphoma entity from a patient with simultaneous papillary renal cell carcinoma following pediatric kidney transplant.
Guazzo R, Fischer A, Vannucchi M, Fabbri A, Garosi G, Granai M, Tripodi SA, Oehl-Huber K, Bens S, Moawia A, Cencini E, Lazzi S, Siebert R, Leoncini L. Guazzo R, et al. Among authors: fabbri a. Pathol Res Pract. 2024 Dec 17;266:155777. doi: 10.1016/j.prp.2024.155777. Online ahead of print. Pathol Res Pract. 2024. PMID: 39708522 Free article.
Tolerability and Preliminary Outcomes of Adjuvant T-DM1 in HER2-Positive Breast Cancer After Neoadjuvant Therapy: The ATD Study.
Krasniqi E, Filomeno L, Arcuri T, Di Lisa FS, Astone A, Cutigni C, Foglietta J, Nunzi M, Rossi R, Minelli M, Meattini I, Visani L, Scialino J, Livi L, Moscetti L, Marchetti P, Botticelli A, Paris I, Pavese F, D'Angelo T, Sini V, Stani S, Valerio MR, Grassadonia A, Tinari N, Mazzotta M, Vergati M, D'Auria G, Gamucci T, D'Onofrio L, Gasparro S, Roselli A, Fulvi A, Ferretti G, Torchia A, Giordano M, Greco F, Pantano F, Tonini G, Fabbri A, Bria E, Garufi G, Fiorio E, Raffaele M, Pistelli M, Berardi R, Saltarelli R, Kayal R, Ferranti FR, Cannita K, Irelli A, D'Ostilio N, De Rossi C, Palumbo R, Cariello A, Sanguineti G, Calabrò F, Pizzuti L, Barba M, Botti C, Pelle F, Cappelli S, Cavicchi F, Puccica I, Villanucci A, Sperduti I, Ciliberto G, Vici P. Krasniqi E, et al. Among authors: fabbri a. Cancers (Basel). 2024 Dec 7;16(23):4104. doi: 10.3390/cancers16234104. Cancers (Basel). 2024. PMID: 39682290 Free PMC article.
948 results